stockrow
Saturday 7 November 2026
Export OCGN’s income statement to Excel — free account
Ocugen, Inc.
OCGN Healthcare Biotechnology
Ocugen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.4 million, up 8.83% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- +84.9%
- Free cash flow
- −22.2%
- Total debt
- −93.7%
Quarter to September 2026, against a year earlier
0.93
0.11
+13.41%
Follow OCGN
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
73.11 | 113.14 | 132.78 | 91.83 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(22.20) | (42.48) | (27.20) | (29.03) | |
P/B ratio |
0.00 | 0.00 | 102.13 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 105.77 | 0.00 | |
EV/Sales |
55.85 | 91.68 | 132.18 | 94.14 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.19) | (6.90) | (9.94) | (7.29) | |
EV/FCF |
(4.18) | (6.88) | (9.91) | (7.27) | |
Quick Ratio |
0.71 | 0.75 | 1.54 | 0.81 | |
Current Ratio |
0.77 | 0.80 | 1.86 | 1.06 | |
Net Debt/EBITDA |
5.02 | 7.05 | 0.16 | (0.64) | |
Debt/Assets |
1.65% | 1.41% | 51.30% | 66.16% | |
Debt/Equity |
(0.10) | (0.11) | 5.03 | (2.37) | |
Asset Turnover |
0.06 | 0.05 | 0.07 | 0.07 | |
Operating CF/Net income |
4.37 | 0.49 | 1.14 | 0.79 | |
Capex/Depreciation |
(0.11) | (0.01) | (0.01) | (0.04) | |
Interest Coverage |
(5.75) | (3.67) | (13.51) | (12.76) | |
Research and Development Expense of Revenue |
640.70% | 718.41% | 734.18% | (5,528.50%) | |
Selling, General and Administrative Expense of Revenue |
369.25% | 486.69% | 529.48% | (3,177.20%) | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
100.21% | 123.19% | 221.66% | (1,037.31%) | |
Graham Net Nets |
(0.10) | (0.07) | (0.02) | (0.08) | |
Graham Number |
0.49 | 0.53 | 0.00 | 0.46 | |
Earnings Yield |
(19.48%) | (16.99%) | (13.26%) | (17.04%) | |
Free Cash Flow Yield |
(18.29%) | (11.78%) | (10.05%) | (14.10%) | |
Revenue per Share |
0.01 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.05) | (0.04) | (0.07) | (0.05) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.05) | (0.04) | (0.07) | (0.05) | |
Cash per Share |
0.25 | 0.30 | 0.10 | 0.06 | |
Shareholders Equity per Share |
(0.05) | (0.05) | 0.02 | (0.04) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.05) | (0.05) | 0.02 | (0.04) | |
Free Cash Flow |
(15.89) | (12.22) | (21.80) | (14.00) | |
Working Capital |
(27.47) | (26.36) | 17.84 | 1.30 | |
Capital Expenditures |
(0.15) | (0.02) | (0.01) | (0.03) | |
Net Current Asset Value |
(34.31) | (34.04) | (12.55) | (31.34) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.08 | 0.01 | 0.00 | (0.18) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
4.82 | 4.69 | 3.23 | 5.22 | |
Average Assets |
82.83 | 88.90 | 60.68 | 62.98 | |
Average Common Equity |
(7.07) | (6.75) | 10.86 | 8.73 |
Columns are period end dates · fundamentals updated 6 Nov 2026